continuous venovenous hemodialysis
Recently Published Documents


TOTAL DOCUMENTS

94
(FIVE YEARS 11)

H-INDEX

20
(FIVE YEARS 2)

2020 ◽  
Vol 24 (4) ◽  
Author(s):  
Cenk Gokalp ◽  
Aysun Fatma Dogan ◽  
Guray Aygun ◽  
Ilhan Kurultak ◽  
Sedat Ustundag

2020 ◽  
Author(s):  
Ankit Patel ◽  
Kenneth B Christopher

Renal replacement therapy (RRT) can be used to support patient’s kidney function in cases of acute kidney injury (AKI). However, timing, modality, and dosing of RRT continue to remain in question. Recent studies have begun to provide data to help guide clinicians on when to initiate RRT, what form of RRT to use ranging from continuous venovenous hemofiltration (VVH) to intermittent hemodialysis, and the impact of high versus low-intensity dosing. Additionally, the risks associated with temporary vascular access with regard to thrombosis and infection, the impact of high efficiency and flux versus low efficiency and flux membranes, and options for anticoagulation in RRT for AKI are also discussed. This review contains 75 references.  Key words: acute kidney injury, chronic kidney disease, continuous venovenous hemofiltration, continuous venovenous hemodialysis, renal replacement therapy, venovenous hemofiltration, 


2020 ◽  
Vol 49 (3) ◽  
pp. 281-288 ◽  
Author(s):  
Alfonso Maria Califano ◽  
Laurent Bitker ◽  
Ian Baldwin ◽  
Nigel Fealy ◽  
Rinaldo Bellomo

Background: Continuous renal replacement therapy (CRRT) technique may affect circuit lifespan. A shorter circuit life may reduce CRRT efficacy and increase costs. Methods: In a before-and-after study, we compared circuit median survival time during continuous venovenous hemofiltration (CVVH) versus continuous venovenous hemodialysis (­CVVHD). We performed log-rank mixed effects univariate analysis and Cox mixed effect regression modeling to define predictors of circuit lifespan. Results: We compared 197 ­CVVHD and 97 CVVH circuits in 39 patients. There was no overall difference in circuit lifespan. When no anticoagulation was used, median circuit survival time was shorter for CVVH circuits (5 h, 95% CI 3–7 vs. 10 h, 95% CI 8–13, p < 0.01). Moreover, CVVHD, lower platelets levels, and longer activated partial thromboplastin time independently predicted longer circuit median survival time. Conclusions: CVVHD is associated with longer circuit median survival time than CVVH when no anticoagulation is used and is an independent predictor of circuit survival.


2020 ◽  
Vol 48 (1) ◽  
pp. 680-680
Author(s):  
Nicholas Quinn ◽  
Gretchen Sacha ◽  
Matthew Wanek ◽  
Jason Yerke ◽  
Pavithra Srinivas ◽  
...  

2019 ◽  
Vol 41 (4) ◽  
pp. 544-546 ◽  
Author(s):  
Mehdi Oualha ◽  
Jean-Marc Tréluyer ◽  
Despina Moshous ◽  
Marie-Elisabeth Bougnoux ◽  
Julie Starck ◽  
...  

2019 ◽  
Vol 44 (1) ◽  
pp. 91-99 ◽  
Author(s):  
Grzegorz Niewinski ◽  
Joanna Raszeja‐Wyszomirska ◽  
Marta Hrenczuk ◽  
Agata Rozga ◽  
Piotr Malkowski ◽  
...  

2019 ◽  
Vol 41 (3) ◽  
pp. 376-382 ◽  
Author(s):  
Teresa Tenorio-Cañamás ◽  
Santiago Grau ◽  
Sonia Luque ◽  
Jesús Fortún ◽  
Fernando Liaño ◽  
...  

2019 ◽  
Vol 70 (1) ◽  
pp. e181
Author(s):  
Grzegorz Niewinski ◽  
Joanna Raszeja-Wyszomirska ◽  
Marta Hrenczuk ◽  
Agata Rozga ◽  
Piotr Malkowski ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document